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Tuberculosis in North Korea
Tuberculosis (TB) has long been one of
the most serious public health problems in
North Korea (Democratic People’s Re-
public of Korea). The estimated TB
incidence of 345/100,000 population is
higher than in some countries with
generalized HIV/AIDS epidemics [1].
HIV is thought to be almost nonexistent
in North Korea, but chronic malnutrition,
an important risk factor for TB, has
become a fact of life for much of the
population since the 1990s [2]. The North
Korean health care system has been
devastated by the economic problems of
the past two decades, making it difficult to
respond to poverty- and nutrition-related
diseases such as TB [3]. In 1998, the
Ministry of Public Health (MOPH) adopt-
ed DOTS (Directly Observed Treatment,
Short-course), the World Health Organi-
zation (WHO)-recommended approach
for TB control in resource-limited settings.
The major components of DOTS—spu-
tum smear microscopy for diagnosis, and
standardized regimens of quality-assured
drugs for treatment—had not been as
strongly emphasized in North Korea
previously. In 2003, North Korea began
procurement of TB drugs from the Global
Drug Facility (GDF), a WHO-led initiative
that has supplied high-quality drugs to
over 90 countries since its inception in
2001 [4]. In 2010, the Global Fund to
Fight AIDS, TB and Malaria (GFATM)
began a five-year, US$41.1M project to
continue and expand these initiatives [5].
UNICEF, the principal recipient, and
WHO, the technical lead, are responsible
for implementation of this project.
Little of this international aid has
included treatment of drug-resistant TB.
For example, in 2011, North Korea
reported 85,564 new cases of TB, the vast
majority of whom would have received the
GDF standard treatment kit for new
patients (category I), a red/white card-
board box containing two months of
isoniazid, rifampicin, ethambutol, and
pyrazinamide, followed by four months
of isoniazid and rifampicin. There were
also 13,507 patients with a past history of
TB treatment who would have received
the GDF standard retreatment kit (cate-
gory II): two months of streptomycin
injections plus isoniazid, rifampicin, eth-
ambutol, and pyrazinamide, followed by
one month of isoniazid, rifampicin, eth-
ambutol, and pyrazinamide, followed by
five months of isoniazid, rifampicin, and
ethambutol. These two regimens have
been shown to be highly effective for
drug-susceptible TB, but are significantly
less effective for drug-resistant TB [6].
There has never been any clear scien-
tific evidence that drug-resistant TB is a
serious problem in North Korea. North
Korea does not have any system for drug
resistance surveillance, nor has it ever
performed a national or subnational drug
resistance survey [7]. The GFATM focus
on treatment for drug-susceptible TB
would make programmatic sense if the
overall proportion of North Korean TB
patients with drug resistance were low. In
such settings, improving the diagnosis and
treatment of drug-susceptible TB can
prevent the creation of drug resistance. It
is much more difficult to diagnose and
treat drug-resistant TB, particularly mul-
tidrug-resistant (MDR) TB, defined as
resistance to isoniazid and rifampicin, the
two strongest TB drugs and the backbone
of standard DOTS regimens. MDR TB
requires 18–24 months of treatment with
expensive and poorly tolerated second-line
TB drugs.
In the absence of drug resistance
surveillance data, the successful implemen-
tation of DOTS has suggested that drug
resistance should not be a problem in
North Korea. According to WHO, the
outcomes for new smear-positive patients
receiving category I in 2010 were 86%
cured, 4% completed, 3% died, 4% failed,
2% defaulted (1% not evaluated). Out-
comes of retreatment patients (category II)
were 76% cured, 8% completed, 4% died,
8% failed, 3% defaulted (2% not evaluat-
ed) [1]. North Korea is one of the few
countries in the world that have attained
the WHO target of 90% success (cured
plus completed) for new patients, a
monumental achievement given the chal-
lenges faced by the MOPH. WHO
programmatic indicators, however, can
exaggerate cure rates because they rely
on the relatively insensitive tool of smear
microscopy. A patient who is sputum
smear-negative after completing a stan-
dard DOTS regimen is considered to be a
cure, even if there is a small amount of
viable bacteria in the sputum that would
be detectable by a more sensitive test like
culture. This is rarely an issue in settings
where almost all TB is drug-susceptible,
but in settings where drug-resistant TB is
more common, such as Siberia, WHO
indicators can overestimate the efficacy of
standard DOTS regimens [8,9].
The experience of countries such as
Russia, Azerbaijan, and Uzbekistan,
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which like North Korea experienced
economic hardship after the collapse of
the Soviet Union, suggests that drug-
resistant TB may already be a serious
problem in North Korea. In these coun-
tries, the breakdown of health systems and
social services was followed rapidly by the
spread of MDR strains. These countries
continue to struggle with some of the
highest rates of MDR TB in the world [1].
EugeneBell’s Experience in
North Korea
EugeneBell is a name shared by two
non-governmental organizations (NGO),
one American, the Eugene Bell Founda-
tion, and one South Korean (Republic of
Korea), EugeneBell Korea, which have
supported North Korean TB sanatoria
throughout the country for over a decade
with medicines, equipment, and consum-
ables [10]. On the basis of our experience
of working with North Korean TB pa-
tients, anecdotal reports from North
Korean clinicians, and the original data
that is presented here, we believe that the
spread of MDR TB is much more
advanced than previously assumed.
North Korea has a network of TB
sanatoria similar to those that were
common in the United States and Europe
in the pre-antibiotic era. Dozens of
sanatoria exist throughout the country,
generally in rural areas, each housing tens
to hundreds of patients in cramped
conditions. In the past, sanatoria may
have admitted only those TB patients who
needed injections or who were too sick to
take care of themselves at home. But after
the widespread implementation of DOTS,
many North Korean sanatorium clinicians
have reported to us that an increasing
number of patients do not seem to be
responding to treatment with standard
DOTS regimens.
In 2007, after extensive discussions
between the MOPH and EugeneBell,
six sanatoria in North/South Pyongan
provinces and Pyongyang and Nampo
cities were designated by the MOPH as
MDR TB treatment centers. The com-
bined patient census of these six sanato-
ria is approximately 800. As part of the
new treatment program, we began to
develop a system for testing patients for
drug resistance. Sputum samples were
collected during EugeneBell delegation
visits scheduled at six-month intervals.
Before each visit, North Korean clini-
cians pre-selected patients with a history
of treatment failure with standard DOTS
regimens. Most patients had previously
received two or more courses of treat-
ment with DOTS regimens, including
category II. Sputum specimens were
transported to the Korean Institute of
Tuberculosis, a South Korean laboratory
that is part of the supranational reference
laboratory network that monitors drug-
resistant TB globally [1]. Culture and
susceptibility testing were performed on
Lo¨wenstein-Jensen media to first- and
second-line drugs. Pyrazinamide suscep-
tibility was determined using the pyrazi-
namidase test.
Figure 1 shows the results of drug
susceptibility testing of all 245 culture-
positive candidates for MDR TB treat-
ment that were presented to EugeneBell
during three visits spanning April 2010 to
April 2011. Of these, 175 (67%) were
men. The median age was 40 (range 32–
46). Two-hundred and thirteen (87%)
patients were diagnosed with MDR TB
(resistance to isoniazid and rifampicin).
Thirty-five (14.3%) were diagnosed with
MDR plus resistance to a second-line
injectable (kanamycin or capreomycin),
and 21 (8.6%) were diagnosed with MDR
plus resistance to ofloxacin. Six patients
(2.4%) were diagnosed with extensively
drug-resistant (XDR) TB (MDR plus
resistance to a second-line injectable and
ofloxacin). The most common MDR
patterns are shown in Table 1.
How Much MDR TB Is There in
North Korea?
These resistance data are from a
convenience sample of high-risk patients
enrolling in a clinical treatment program,
and cannot be assumed to be representa-
tive of the general TB population. But in
the absence of national surveillance data,
these data are disturbing. The patient data
reported here likely represent a large pool
of chronic MDR TB patients that has
been growing for years due to the absence
of effective treatment.
Strains resistant to second-line TB
drugs, including some XDR strains, were
present in the patients tested by Eugene-
Bell. Since all patients were tested prior to
enrolment in the EugeneBell treatment
program, this suggests that some patients
had taken second-line TB drugs previous-
ly, or had been infected by someone who
had. Without access to effective treatment
within formal health systems, North Ko-
rean MDR TB patients, like MDR TB
patients in other countries, will turn to
informal systems to obtain second-line TB
drugs. Such drugs will inevitably be
inadequate in quantity or quality, and
likely to result in even more highly
resistant strains that can be transmitted
to family and neighbors.
Drug resistance surveillance studies are
urgently needed to estimate the prevalence
of MDR TB in the general TB patient
population. WHO estimates there are
approximately 3,500 MDR TB cases per
year in DPRK, on par with relatively low
MDR prevalence countries in the region
like India (2.1% of new cases and 15% of
retreatment cases). If North Korea’s MDR
rates were similar to China (5.7% of new
cases and 26% of retreatment cases), there
would be more than 8,000 MDR TB cases
per year. In a worst case scenario, if North
Korea’s MDR rates were similar to Russia
(20% of new cases and 46% of retreatment
cases), there would be over 23,000 MDR
TB cases per year [1].
Rapid Scale-up of MDR-TB
Treatment Is Urgently Needed
in North Korea
At the current time, the most urgent
problem in North Korea is the lack of
access to the second-line TB drugs needed
to treat MDR TB. MDR TB treatment
regimens are hundreds of times more
Summary Points
N In the absence of surveillance data, international aid to the North Korean
national tuberculosis (TB) program has largely ignored the possibility that drug-
resistant TB strains are widespread, as is the case in Russia and China.
N EugeneBell, a non-governmental organization (NGO) that works with North
Korean TB patients, believes that spread of multidrug-resistant (MDR) TB in
North Korea is much more advanced than previously assumed, based on
anecdotal reports from North Korean clinicians and data collected from TB
sanatoria.
N Until effective treatment can be made available to them, MDR TB patients will
continue to be a source of transmission to families, neighbors, health providers,
and other patients.
N Rapid scale-up of MDR TB treatment is possible in North Korea, but only if the
international community—including donors, NGOs and governments—takes
the threat of MDR TB seriously.
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expensive than the first-line DOTS regi-
mens used to treat drug-susceptible TB.
Many resource-limited countries are only
able to procure second-line TB drugs
through international funding mecha-
nisms such as the GFATM. In North
Korea, however, the GFATM workplan
includes procurement of hundreds of
thousands of GDF category I and II
treatment kits, but only 500 MDR TB
treatment courses during the first four
years of the project [11].
The lack of laboratory capacity for
diagnosis of MDR TB is equally worri-
some. The GFATM project focuses mostly
on strengthening the national smear mi-
croscopy network. North Korea still does
not have a TB laboratory accredited to
perform drug susceptibility testing, though
an international initiative to create such a
laboratory in Pyongyang has been under-
way since 2009 [12,13]. Ultimately, much
more laboratory capacity will be needed to
screen over 15,000 retreatment patients
annually for MDR TB and to monitor the
thousands of MDR TB patients that need
treatment.
Since second-line TB drugs have been
largely unavailable outside the few MDR
TB treatment sites supported by Eugene-
Bell, most North Korean clinicians have
no other option except to prescribe
repeated courses of first-line TB drugs to
patients suspected of having MDR TB.
MDR TB patients who are treated
empirically with the standard DOTS
regimens may become transiently sputum
smear-negative and deemed ‘‘cured’’
[14]. When they become smear-positive
again, these patients are categorized as
‘‘relapses’’ according to national TB
treatment guidelines and treated with
the standard DOTS regimen for retreat-
ment patients. Before being diagnosed
with MDR TB by EugeneBell, most of
the patients included in this report had
already received multiple courses of
treatment with standard DOTS regimens
of first-line drugs that were mostly
ineffective. This dangerous practice is
likely to be a major factor in the creation
of MDR strains in North Korea via the
Figure 1. Drug resistance in North Korean sanatorium patients (n = 245). The TB Ag MPT64 Rapid kit (SD Bioline), an
immunochromatographic test using mouse monoclonal antibodies to detect the MPT64 protein, was used on positive cultures for identification
of Mycobacterium tuberculosis complex. Critical concentrations were as follows (mcg/ml): isoniazid 0.2, rifampicin 40.0, ethambutol 2.0, streptomycin
10.0, kanamycin 40.0, amikacin 40.0, capreomycin 40.0, ofloxacin 2.0, prothionamide 40.0, cycloserine 30.0, para-aminosalicylic acid (PAS) 1.0.
Pyrazinamide susceptibility was determined using the pyrazinamidase test.
doi:10.1371/journal.pmed.1001486.g001
Table 1. Common MDR patterns in North Korean sanatorium patients (n= 245).
Resistance pattern Percent (number)
MDR without second-line drug resistance 62% (152)
Isoniazid and rifampicin 12% (30)
Isoniazid, rifampicin, and ethambutol 3% (8)
Isoniazid, rifampicin, and streptomycin 21% (52)
Isoniazid, rifampicin, ethambutol, and streptomycin 18% (43)
Isoniazid, rifampicin, ethambutol, streptomycin, and pyrazinamide 4% (10)
MDR with second-line drug resistance 25% (61)
MDR with second-line injectable resistance 14% (35)
MDR with ofloxacin resistance 9% (21)
XDR 2% (6)
doi:10.1371/journal.pmed.1001486.t001
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amplifier effect of short-course chemo-
therapy [15,16].
Given the urgent need for MDR TB
treatment, EugeneBell has stepped into
the aid vacuum and has provided support
for the North Korean MDR TB treatment
program, including second-line TB drugs,
laboratory equipment and consumables,
and clinical training for North Korean
doctors and nurses, who have generally
shown exceptional dedication and motiva-
tion to treat these most difficult of TB
patients. Our budget is small compared to
many of the international organizations
already supporting the North Korean TB
program, but it is almost completely
funded by individuals and churches that
are drawn to our objective of complete aid
transparency. In this manner, EugeneBell
acts as a channel for private citizens in
North Korea, South Korea, and the US to
cooperate and address a serious public
health problem.
We have uncovered evidence of a
growing MDR TB epidemic, and have
demonstrated that North Korean doctors
and nurses are ready to treat MDR TB if
given the tools to do so. National scale-
up of MDR TB diagnosis and treatment,
however, will require significantly more
resources. The progress of this project
has shown that MDR TB treatment
scale-up can and should be a major
component of North/South cooperation.
A comprehensive response to MDR TB
would include nutritional supplementa-
tion for TB patients, improving housing
for sanatorium patients, increasing labo-
ratory capacity to do culture and drug
susceptibility testing, procurement of
drugs for MDR/XDR TB, and building
surgical capacity to do pulmonary resec-
tion. Rapid scale-up of MDR TB treat-
ment is possible in North Korea, but
only if the international community—
including donors, NGOs and govern-
ments—takes the threat of MDR TB
seriously.
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